This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Story Behind Sarepta's Firing of its Top Scientist

By: Adam Feuerstein | 07/24/14 - 09:21 AM EDT

Stocks in this article: SRPT

Let's talk about Sarepta Therapeutics (SRPT) and the firing of Chief Scientific Officer Art Krieg. The company announced Krieg's "termination" Thursday in an 8-K filed with the Securities and Exchange Commission but offered no explanation.

The good news: Krieg had no role in the clinical development of eteplirsen, Sarepta's lead Duchenne muscular dystrophy therapy. Krieg wasn't involved with the eteplirsen approval filing or discussions between Sarepta and the FDA. Krieg's firing has nothing to do with eteplirsen, according to two sources familiar with the situation. [Both would not speak on the record.]

The bad news: Krieg was hired last January to run Sarepta's drug discovery and early-stage research programs. But seven months later, Sarepta's effort to bring new drugs into the clinic has fallen behind schedule. Last January at the J.P. Morgan Healthcare Conference, Krieg shared the stage with CEO Chris Garabedian. Both men promised to accelerate the company's RNA therapeutics platform, so that Sarepta was not just about eteplirsen. Those promises have not been kept. I'm told there's been significant disagreements within Sarepta's executive team about strategy and the pace of the work on new exon-skipping drugs. The result: Krieg is gone. 

Sarepta would not comment beyond what was stated in the 8-K filing.

It's not fair to blame one guy for Sarepta's slow pace. Garabedian hired Krieg so he needs to shoulder a lot of the responsibility for the inability of the company to move new drugs quickly into the clinic, as promised. Krieg is not the only Sarepta employee to leave, which reinforces the whispers you hear about Garabedian being a tough CEO to work for.

And while we're discussing rumors, there's the one -- unconfirmed -- about Krieg going to Sarepta's board in an attempt to unseat Garabedian as CEO.

I don't know if the Krieg coup rumor is true, but it does fit in with what I heard about fights between Sarepta's top executives over strategy. And while executives leave companies all the time, the announcements are usually couched with more nuance. Executives resign to spend more time with their families or to pursue new opportunities. It's relatively rare for a company to disclose that an executive was "terminated." When this happens, the board is usually involved, so maybe there is something to the coup rumor. 




Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,801.54 -13.40 -0.08%
S&P 500 2,069.67 +2.64 0.13%
NASDAQ 4,776.0240 +17.7720 0.37%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs